Immutep (IMMP)

Executive Summary

Immutep is a late clinical-stage biotechnology company pioneering LAG-3 immunotherapies for cancer and autoimmune diseases. Its lead asset, eftilagimod alpha (IMP321), is a soluble LAG-3 fusion protein that activates antigen-presenting cells and enhances T-cell responses. The company is advancing a robust pipeline, with the most advanced program being the Phase 2/3 AIPAC-3 trial (NCT05747794) evaluating efti plus paclitaxel in metastatic breast cancer, which is actively enrolling and expected to complete in 2027. Additionally, a Phase 2 trial (NCT07102940) combining efti with TC/AC chemotherapy in early-stage breast cancer is recruiting, and a Phase 2 study (NCT06128863) of efti with pembrolizumab in soft tissue sarcoma is ongoing. Immutep also has early-stage programs, including IMP761, an anti-LAG-3 agonist antibody for autoimmune diseases, currently in a Phase 1 healthy volunteer study (completion expected April 2026). With a market cap of ~$56M, Immutep represents a high-risk, high-reward opportunity, trading at a discount to potential value if key trials succeed. Immutep's near-term strategy focuses on generating proof-of-concept data in breast cancer and potentially expanding into combination regimens. The company maintains a strong intellectual property position in LAG-3 modulation and has a seasoned management team. However, the stock is highly volatile and sensitive to trial results. Key upcoming catalysts include interim data from the Phase 2/3 breast cancer trial and initial safety/efficacy data from the Phase 1/2 sarcoma study. A successful partnership or licensing deal could also provide non-dilutive capital and validation. Investors should monitor enrollment updates and any early data releases for signs of clinical benefit.

Upcoming Catalysts (preview)

• H2 2026Interim data from Phase 2/3 AIPAC-3 trial (efti + paclitaxel) in metastatic breast cancer45% success
• 2026-2027Initial results from Phase 2 trial of efti + TC/AC in early-stage breast cancer (NCT07102940)50% success
• TBDStrategic partnership or licensing deal for LAG-3 platform30% success